Tenax Therapeutics Inc. (NASDAQ: TENX) appointed Timothy Healey as chief commercial officer, effective immediately, according to a company statement.

Healey will oversee the company's global commercial strategy and prepare for the potential launch of TNX-103, the company's drug candidate for pulmonary hypertension with heart failure and preserved ejection fraction.

The pharmaceutical executive previously served as chief commercial officer at Eversana Life Science Services, where he led commercialization efforts for biopharmaceutical companies. He also held senior commercial positions at Lantheus, AbbVie, and AMAG Pharmaceuticals.

"Tim's expertise as an innovative commercial strategist, combined with his history of strong launch execution, makes him uniquely suited to lead Tenax's commercial organization," said Chris Giordano, president and chief executive officer of Tenax Therapeutics.

Healey holds a bachelor's degree from Boston College and an MBA from Babson College. His commercial leadership experience includes recognition as Brandweek's "Marketer of the Year" and leading a team that received Medical Marketing & Media's "Brand Team of the Year" award.

Chapel Hill, North Carolina-based Tenax Therapeutics is developing levosimendan for treating PH-HFpEF, a form of pulmonary hypertension for which no product has received approval. The company is currently in Phase 3 development stage.